Cell and Gene Regulatory

  1. Restore Control When It Matters Most 3/19/2026

    Act with certainty during contamination events. Learn a proven four-step process to identify root causes, restore environmental control, and implement effective CAPAs to prevent recurrence.

  2. The Hidden Costs Of Paper Logbooks 3/19/2026

    Stop losing time and capacity to manual paperwork. Learn how digital workflows eliminate compliance risks and unlock the actionable data needed to optimize life sciences manufacturing.

  3. Integrated Contamination Control Solutions For Biopharma 3/19/2026

    Unlock higher yields and ensure regulatory success with a tailored process optimization program designed to eliminate contamination risks and stabilize biopharmaceutical workflows.

  4. Materials Matter: Ensuring Quality Of CGT Materials 3/19/2026

    Cell and gene therapies are only as strong as the materials behind them; from plasmids and viral vectors to cytokines and other critical components, subtle quality issues can quietly derail promising programs. In this Cell & Gene Live, Anthony Blaszczyk, Ph.D., Senior Scientist at the U.S. Pharmacopeia, and Basak Clements, Ph.D., Founder and Senior Advisor at biomatria, joined Cell & Gene Chief Editor Erin Harris to unpack what today’s CGT leaders need to know about raw, starting, and ancillary materials.

  5. All The Ways Global Biopharma Still Grapples With Annex 1 3/19/2026

    Biopharma companies can't consistently meet Annex 1 expectations. At the heart of the problems, regulators have shifted the burden of proof to manufacturers.

  6. Empower Your Studies With Our Expertise 3/18/2026

    Look at how optimized virus banking strengthens manufacturing by enhancing consistency, speeding characterization timelines, and aligning testing strategies with modern regulatory expectations.

  7. Integrated Quality, Regulatory, And Safety Services 3/18/2026

    A single-vendor model for quality, regulatory, and safety services provides consistent project management and cost-effective scalability. Hear how integrated solutions support market entry and growth.

  8. Industry Innovators: APAC's Sharp Advanced Therapeutics Edge 3/17/2026

    APAC is rapidly advancing its role in the global therapeutics landscape, fueled by faster development models. Learn how this momentum is reshaping expectations for innovation and commercialization.

  9. Why Manufacturing Drives FDA CRLs In Cell Therapy 3/17/2026

    Manufacturing and quality gaps drive most FDA Complete Response Letters in cell therapy, often stemming from early‑stage decisions and unresolved CMC issues that become major late‑stage approval risks.

  10. A Faster Path To Genomic Medicine Feasibility 3/17/2026

    Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.